Enrofloxacin Lactate Powder CAS 730129-77-1

As a professional manufacturer specialized in fluoroquinolone veterinary API synthesis and salt forming purification, we supply high-purity Enrofloxacin Lactate Powder CAS 730129-77-1, synthetic lactate salt quinolone raw material with dual respiratory and intestinal antibacterial spectrum, which differs in molecular salt form, water solubility, target pathogens and applicable breeding scenarios from norfloxacin (first-gen quinolone focusing only on intestinal bacteria) and florfenicol (amphenicol bacteriostatic agent targeting respiratory infections). Produced via closed fluorination synthesis, lactate salt neutralization, multi-stage recrystallization and light-shielded low-temperature drying process, no plant fiber, seaweed or bean endosperm raw materials are adopted in the whole production flow. Our factory maintains stable uniform pale yellow crystalline powder with consistent rapid water dissolution performance, suitable for aquatic pharmaceutical manufacturers, poultry and swine veterinary formulation factories, pet drug plants and large feed premix enterprises. It demonstrates activity against Gram-negative bacteria, Gram-positive bacteria and mycoplasma strains, supporting formulations for mixed respiratory and intestinal infections, a positioning that separates it from norfloxacin's single intestinal application and florfenicol's narrow mixed bacterial spectrum.

We have summarized mainstream procurement pain points reported by global downstream formulation factories purchasing generic enrofloxacin lactate API from intermediate suppliers: unstable HPLC assay leads to inconsistent antibacterial performance of finished soluble powder and injections, high related substances trigger failure in EU residue limit testing, uneven crystal particle size causes incomplete dissolution and turbid drinking water preparations, incomplete GMP certification delays cross-border customs clearance, poor light resistance of low-grade raw materials results in color darkening during long-term storage, and excessive heavy metal content fails overseas veterinary raw material factory audit standards. Low-grade enrofloxacin lactate may contain high residual synthesis and salting solvents, raising the risk of residue testing failure for exported veterinary finished products.

Our factory-produced Enrofloxacin Lactate Powder CAS 730129-77-1 adopts full closed salt-forming recrystallization impurity removal technology, removing fluorination intermediates, lactate excess residues, heavy metal impurities and organic solvents through repeated filtering and gradient recrystallization, with HPLC purity, related substances, pH value and dissolution rate stably controlled within standard ranges batch by batch. Uniform pale yellow crystalline powder features moderate fine particle size for rapid full dissolution in neutral and weakly acidic drinking water, as well as uniform mixing with feed carriers and injection solubilizers. Whole-process light-shielded production reduces photo-induced discoloration risk, meeting global veterinary residue control and clean-label breeding requirements; low ash and low residual solvent indicators lower finished product detection failure probability. Stable batch physical and chemical indicators reduce repeated formulation compatibility testing costs for downstream manufacturers. We support flexible order volumes ranging from 1kg laboratory trial samples to long-term bulk framework contracts, helping livestock, pet and aquatic pharmaceutical factories maintain stable continuous formulation production.

Our internal veterinary R&D team offers free grade selection and dosage suggestions based on your soluble powder, premix and injection formulas.

The core competitive trait of enrofloxacin lactate API belongs to animal-specific second-gen fluoroquinolone series, inhibiting bacterial DNA gyrase and topoisomerase IV to block pathogen DNA replication and realize bactericidal effect, which differs from norfloxacin's single DNA gyrase inhibition and florfenicol's ribosomal protein synthesis suppression mechanism. Its application layout covers simultaneous respiratory and intestinal infection control of multiple breeding species, forming a differentiated track separated from norfloxacin's intestinal-only positioning and florfenicol's livestock respiratory-dominated usage scenarios.

Core Functional Traits of Enrofloxacin Lactate API

Enrofloxacin lactate interferes with two key bacterial enzymes (DNA gyrase & topoisomerase IV), restraining the replication of Gram-negative bacteria, Gram-positive bacteria and mycoplasma strains such as Escherichia coli, Salmonella, Pasteurella, Streptococcus and Mycoplasma gallisepticum, delivering bactericidal activity against sensitive pathogens. It exhibits activity against mycoplasma linked to poultry and swine chronic respiratory disorders, while florfenicol shows limited activity against mycoplasma strains when used alone. After oral administration via feed or drinking water, or intramuscular injection, it achieves rapid absorption and wide tissue penetration, forming stable therapeutic concentration in lung, intestinal tract, joint cavity and reproductive organs, can be used in management plans for mixed bacterial-mycoplasma complications during seasonal disease prevalence periods. It matches multiple dosing modes of large-scale breeding farms, supporting both therapeutic use and metaphylactic group prevention.

The crystalline lactate salt powder can be processed into three mainstream finished veterinary preparations: water-soluble oral powder, feed premix and intramuscular injection, adapting to automatic drinking water dosing systems, feed mixing production lines and sterile injection filling workshops of breeding and pharmaceutical enterprises. It shows stable compatibility with common veterinary auxiliary materials such as glucose carriers, citric acid solubilizers, antioxidants and injection co-solvents, without obvious chemical reaction or efficacy attenuation under conventional mixing and sealed light-proof storage conditions.

All batches of Enrofloxacin Lactate Powder CAS 730129-77-1 comply with Veterinary Pharmacopoeia standards and EU MRL animal residue control limits. Each finished batch completes full chemical, microbial and heavy metal testing in our independent light-shielded GMP laboratory, supporting third-party authoritative testing by SGS, Eurofins and Intertek to meet global veterinary drug registration and factory audit requirements.

All production workshops operate under complete GMP veterinary drug production certification systems. You can apply for full factory audit documents and complete batch COA test reports before placing bulk orders.

New veterinary formulation, pet drug and aquaculture pharmaceutical manufacturers can apply for small test samples to verify HPLC purity, water dissolution speed and mixing uniformity prior to bulk order confirmation.

Hot Tags: enrofloxacin lactate powder cas 730129-77-1, China enrofloxacin lactate powder cas 730129-77-1 manufacturers, suppliers, factory, Albendazole Powder CAS 54965 21 8, CAS 108050 54 0, CAS 70288 86 7, Florfenicol Powder CAS 73231 34 2, Ivermectin powder, Norfloxacin Powder CAS 70458 96 7